Xcell Therapeutics Valuation

Is A373110 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A373110 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A373110's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A373110's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A373110?

Key metric: As A373110 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A373110. This is calculated by dividing A373110's market cap by their current revenue.
What is A373110's PS Ratio?
PS Ratio	27.5x
Sales	₩1.78b
Market Cap	₩49.13b

A373110 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	31.4x
Enterprise Value/EBITDA	-8.2x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does A373110's PS Ratio compare to its peers?

The above table shows the PS ratio for A373110 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	3x
A142760 MOA Life Plus	2.6x	n/a	₩48.0b
A038070 Seoulin BioscienceLtd	0.6x	n/a	₩55.0b
A389030 GENINUS	7.2x	n/a	₩46.5b
A420570 J2KBIO	1.5x	38.3%	₩52.5b
A373110 Xcell Therapeutics	27.5x	n/a	₩49.1b

Price-To-Sales vs Peers: A373110 is expensive based on its Price-To-Sales Ratio (27.5x) compared to the peer average (3x).

Price to Sales Ratio vs Industry

How does A373110's PS Ratio compare vs other companies in the KR Biotechs Industry?

26 Companies	Price / Sales	Estimated Growth	Market Cap
A006280 GC Biopharma	0.9x	9.0%	US$1.10b
A096530 Seegene	2.7x	15.7%	US$752.28m
A086900 Medy-Tox	3.5x	12.5%	US$617.30m
A005250 Green Cross Holdings	0.3x	n/a	US$462.39m

26 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: A373110 is expensive based on its Price-To-Sales Ratio (27.5x) compared to the KR Biotechs industry average (9.2x).

Price to Sales Ratio vs Fair Ratio

What is A373110's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A373110 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	27.5x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A373110's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Bioneer

₩509.0b

Operates as a biotechnology company in South Korea, the Americas, Europe, Asia, Africa, and internationally.

A064550

₩19,910.00

-0.7%

-34.6%

Hugel

₩3.0t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩271,000.00

-1.8%

76.5%

J2KBIO

₩53.0b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,180.00

-4.8%

n/a